Introduction
Poly(ADP-ribosyl)ation of proteins, first reported in 1963, 1 involves the transfer of multiple ADP-ribose units from substrate NAD + onto glutamate residues of the target proteins, resul-ting in the formation of polyanionic poly(ADP-ribose) (PAR) polymers. There has been much research effort since to characterise the structures and functions of the poly(ADP-ribose)-polymerases (PARPs), the family of enzymes responsible for catalysis of this reaction. [2] [3] [4] [5] PARP-1 is responsible for most of the poly(ADP-ribosyl)ation activity in the cell and has a major role in regulating the repair of damaged DNA. It is a 116 KDa protein with three major domains: an N-terminal DNA-binding domain carrying three zinc fingers, 6 a central automodification domain (containing also a nuclear localisation signal 7 and sites for cleavage by caspase-3 8 ) and a C-terminal NAD + -binding catalytic domain. The catalytic activity of the PARP-1 is activated by detection of a damaged site and PAR is built up on histone-1 and on PARP-1 itself. Inhibition of PARP-1 therefore inhibits repair of damaged DNA and several inhibitors of this enzyme are currently in clinical trial as sensitisers to the effects of cytotoxic DNA-damaging drugs in several tumours and as single-agent therapies in BRCA-mutant breast cancer. [9] [10] [11] [12] [13] [14] In addition to its role in regulating repair of damaged DNA, PARP-1 also regulates NF-κB and processes and molecules downstream therefrom. Thus inhibitors of the catalytic activity of PARP-1 have shown interesting activity in vivo in models of several disease states, including haemorrhagic shock, myocardial infarction, stroke and other ischaemiareperfusion injuries, as well as in inflammatory disorders and reproductive health. [15] [16] [17] [18] [19] [20] Recently, inhibitors of PARP-1 have also been shown to inhibit angiogenesis and metastasis in cancer. [21] [22] [23] PARP-2 is a 62 KDa protein with three functional domains. 24 The N-terminal DNA-binding domain lacks zinc fingers but is rich in basic amino-acids, which account for the binding to DNA. The differences in structure of the DNA-binding domains of PARPs 1 and 2 may also reflect the differences in the DNA structures which the two enzymes recognise and the fact that PARP-2 binds to single-strand breaks (SSBs) less efficiently than does PARP-1. The automodification domain is also responsible for the protein-protein interactions that PARP-2 shares with various partners, including PARP-1, XRCC1 and DNA ligase 3. 25 The catalytic domain of mouse and human PARP-2 are highly conserved and both show high homology with the human PARP-1 catalytic domain (69% in the case of human PARP-2). 24 This isoform accounts for approximately 5-10% of the total cellular PARP activity. 25 It can heterodimerise with PARP-1 and it shares many functions and targets. However, PARP-2 has some different protein targets and potential functions. Schreiber et al. 25 showed that PARP-2 -/-mouse embryonic fibroblasts have delayed repair of alkylated bases in DNA following treatment with N-methyl-N-nitrosourea (MNU) and suggest that the PARP-1 / PARP-2 heterodimer is important for efficient base-excision repair. By contrast, Fisher et al. 26 found that a reduction in PARP-1 significantly reduced the rate of repair of single-strand breaks in DNA but reduction in PARP-2 had only a minor effect. PARP-2 interacts with TRF2, 27 a telomerebinding regulatory protein, and affects its ability to bind to DNA both through a non-covalent interaction of PAR with the DNA-binding domain of TRF2 and through a covalent modification at the dimerisation domain. PARP-2 may have a functional role in the maintenance of telomeres but further work using selective inhibitors of this isoform are required to gain insights into the precise molecular mechanisms at work. Antisense knockdown of PARP-2 in a mouse model of colitis resulted in improvement in inflammation and normalisation of colonic function. 28 Deletion of PARP-2 but not of PARP-1 leads to a significant diminution in CD4 + CD8 + double-positive thymocytes, 29 suggesting that PARP-2 has a role in survival of Tcells during thymopoiesis and may regulate the apoptosis of thymocytes. PARP-2 is widely expressed in the seminiferous epithelium, in contrast to limitation of PARP-1 to the peripheral cell layer, 25, 30 pointing to distinct roles in spermatogenesis and a more prominent role for PARP-2. PARP-2 knockout mice display lipodystrophy, 31 probably due to regulation of the expression of peroxisome proliferator-activated receptor-γ by PARP-2. The identification of these roles for PARP-2 which are distinct from those of the major isoform PARP-1 32 point to the need for selective inhibitors initially as pharmacological tools to help resolve and distinguish the roles of PARP-2 but also, in the longer term, possibly as drugs.
Most attempts to identify PARP-2-selective inhibitors have relied on screening libraries of inhibitors of PARP-1 against both isoforms. Interestingly, most of the clinical candidate PARP-1 inhibitors and of the widely used pharmacological tool inhibitors display little or no selectivity and thus any pharmacological effect thereof must be regarded as the effect of pan-PARP inhibition or, at minimum, of PARP-1 and PARP-2 together. As shown in this paper, our lead PARP-1 inhibitor 5-aminoisoquinolin-1-one 1 (5-AIQ, Figure 1 ), which is potently active in vivo, 15, [17] [18] [19] [20] 23 is devoid of isoform-selectivity in vitro. Similarly, two other standard PARP-1 was the most selective, with IC 50 (PARP-1) = 13 nM and IC 50 (PARP-2) = 500 nM (selectivity ratio = 39); minor modifications to the substitution on the fluorophenyl ring were tolerated in the structure-activity relationship (SAR) but the long pendant 3-(4-aryl-1,2,5,6-tetrahydropyridin-1-yl)propyl group at the 3-position of the quinazolinone was shown to be essential in this series, as 5-chloro-2-methylquinazolin-4-one was non-isoform-selective and was 92-fold less active against PARP-1 than was 8. 38 The same paper also reports that 9a was some twelvefold more potent as an inhibitor of PARP-2 than it was of PARP-1; other varied substituents in the 4-position of the phenyl were tolerated with little loss of selectivity. 38 The observed selectivities were rationalised by examining X-ray structures of co-crystals of PARP-1 with inhibitors and of homology models of PARP-2. Separately, this group also reported that a 2-aryl-quinoxaline-5-carboxamide 9b had 5-fold selectivity for inhibition of PARP-2. 39 By far the most selective inhibitors of PARP-2 claimed to date are a series of 5-benzoyloxy and 5-phenacyloxy-isoquinolin-1-ones and 3,4-dihydroisoquinolin-1-ones, of which 10 and 11 appear to show 60-fold and 16-fold selectivity, respectively. 33 These compounds, which pick up the usual PARP-binding contacts of the classical (3,4-dihydro)isoquinolin-1-one pharmacophore, achieve their selectivity by relatively weak micromolar binding to PARP-1, rather than great potency against PARP-2. This poor binding to PARP-1 is probably due to the 5-benzoyloxy and 5-phenacyloxy substituents being too large to be accommodated in the slightly smaller hydrophobic binding pocket of PARP-1, as compared to that of PARP-2 (see below).
In the present work, we report on two different approaches to the discovery of PARP-2-selective inhibitors, both based on the isoquinolin-1-one core which gives good binding to both isoforms through the hydrogen-bonding network to the lactam oxygen and N-H and through π-stacking of the aromatic ring to the adjacent Tyr residues (Tyr 907 / Tyr 449 ).
Chemical synthesis
Noting the remarkable selectivity for inhibition of PARP-2 by 10 claimed by Pellicciari et al., 33 we sought to use this core to develop further selective inhibitors of this isoform. Inhibitors 10 and 11 both contain O-aryl esters, which are likely to be labile to hydrolysis in physiological media. To obviate this potential problem, the ester was replaced by an amide in target compound 15a (Scheme 1); this amide should be isosteric but may restrict rotation in this part of the molecule.
Synthesis of 15a and its analogues 15b-n required quantities of 1. This compound is commercially available but is prohibitively expensive for applications in synthesis. There are three previous published syntheses of 1 (where the critical steps are: a Polonowski rearrangement 5-nitroisoquinoline-N-oxide, 40 reductive cyclisation of methyl 2-cyanomethyl-3-nitrobenzoate 41 and by condensation of methyl-2-methyl-3-nitrobenzoate with dimethylformamide dimethylacetal 15 ) but all have severe limitations. Thus, for large-scale preparation of 1, a new synthesis was needed, with requirements for high yield and avoidance of scale-limiting steps such as column chromatography. Scheme 1 shows our development of this important new route. In this route, the 5-nitrogen substituent is introduced by nitration. However, the most nucleophilic position of isoquinolin-1-ones is 4-C, 42 so direct nitration of isoquinolin-1-one was not feasible. The activating enamide function of isoquinolin-1-one was masked as the iminochloride in 12. Commercially available 1-chloroisoquinoline 12 was nitrated selectively in the 5-position in 92% yield; to achieve this regioselectivity, it was necessary to pre-dissolve 12 in conc. sulfuric acid to ensure that the heterocyclic ring was fully protonated and deactivated before addition of the nitrating reagents. The imino-chloride in 13 was hydrolysed by heating in acetic acid to provide 14 in high yield and catalytic hydrogenation of the nitro group, under conditions previously reported, 42 then furnished 1. This new sequence is reliable, highyielding (54% overall), highly reproducible and involves only two intermediate recrystallisat-
ions and no chromatography for purification, giving the potential for it to be used on larger scales.
5-Benzamidoisoquinolin-1-one 15a was synthesised in good yield by acylation of 1 with benzoyl chloride in hot pyridine (Scheme 1); the relatively forcing conditions were required to overcome the poor nucleophilicity of the exocyclic amine in 1 and to ensure good solubility.
To explore the structure-activity relationships around this the phenyl ring, a series of 5-(substituted-benzamido)isoquinolin-1-ones 15b-j were prepared similarly from 1 and substituted benzoyl chlorides. Following a classical medicinal chemical replacement of the benzene aromatic ring with thiophene led to design of 5-(thiophen-2-ylcarboxamido)isoquinolin-1-one 15k, which was prepared from 1 with thiophene-2-carbonyl chloride. The need for aromaticScheme 1. New efficient synthesis of 1 and synthesis of 5-(acylamino)isoquinolin-1-ones 15a-n. Reagents and conditions: i, HNO 3 , H 2 SO 4 , 0°C, 92%; ii, AcOH, 100°C, 82%; iii, H 2 , Pd/C, EtOH, aq. HCl, 66%; iv, RCOCl, pyridine, 90 o C, 86% (15a), 82% (15b), 71% (15c), 72% (15d), 68% (15e), 77% (15f), 81% (15g), 76% (15h), 63% (15i), 61% (15j), 51% (15k), 68% (15l), 68% (15m), 59% (15n). In 2004, the crystal structure of the catalytic fragment of murine PARP-2 was solved 48 at 2.8 Å resolution, seven years after the data for the chicken PARP-1 catalytic fragment were made available. 49 The high degree of homology of the PARP catalytic domain between different species means that PARP inhibitors are unlikely to show a wide species-difference in their binding of inhibitors between chicken, mouse and human PARPs, for a specific isoform. In the first three compounds, the carboxylic acid was attached to the 5-position of the isoquinolin-1-one through all-carbon links (Scheme 3). Compound 24 was prepared by hydrolysis of 5-cyanoisoquinolin-1-one 23. 51, 52 The targets 26 and 27 have a C 2 chain between the carboxylic acid and the isoquinoline, the former with a rigid link and the latter with a flexible link.
These were approached by a Heck coupling of 5-iodoisoquinolin-1-one 25 to give 26. 52 Selective hydrogenation of the exocyclic double bond under acidic conditions led to 27. 
Biochemical and cell biological evaluation
The two series of 5-substituted isoquinolin-1-ones were evaluated in vitro for inhibition of the catalytic activities of full-length active human PARP-1 isolated from HeLa cell nuclear extract (using a FlashPlate assay previously developed by us 55 ) and full-length mouse PARP-2 (using a solution-phase assay); the results are presented in Table 1 Curiously, the benzoate ester 10, which is claimed to be the most selective for inhibition of PARP-2 with a reported ratio of IC 50 values ca. 60, 33 had activity against PARP-2 very similar to that of the close analogue, the benzamide 15a, as expected, but proved to be potent in our assay of inhibition of PARP-1 catalytic activity, giving a selectivity ratio of only 2.75.
The quinoxaline-5-carboxamide 9b was remarkably potent against both isoforms, with IC 50 = 30 nM vs. PARP-1 and IC 50 = 90 nM vs. PARP-2. These values give an approximate 3-fold selectivity for inhibition of PARP-1, in contrast to the claimed 5-fold selectivity for PARP-2. 39 These marked differences in apparent selectivities for the different isoforms probably arise from the different assays used and different sources of the enzymes used. Pellicciari et al. 33 compared bovine PARP-1 with murine PARP-2 using the incorporation of radioactivity from 3 H-NAD + into trichloroacetic acid-insoluble material as an assay of enzymic activity, whereas Iwashita et al. 39 compared human PARP-1 with murine PARP-2 using the same method. 60 We compared human PARP-1 with murine PARP-2 using different assay methods.
Thus it is highly likely that our comparative assays are a much more stringent test of selectivity for inhibition of PARP-2 than the assay pairs previously used or, alternatively, tend to bias towards reporting selectivity for inhibition of PARP-1. for PARP-1 and for PARP-2, isoquinolinone-5-carboxylic acid 24 showed little inhibition of either isoform, a surprising result in view of the observation of IC 50 < 13 μM in an earlier assay using broken cell nuclei as the source of PARP activity. 51 The isoquinolin-1-ones 26, 27
and 29 carrying the carboxy group attached to the 5-position through a more-or-less flexible linker were active against both isoforms but with modest selectivity. The isoquinolinone-5-propenoic acid had previously shown IC 50 < 11 μM in the broken nuclei assay against mixed PARPs, broadly consistent with the presently observed values in the purified enzyme assays. 51 Curiously, 32, which bears the carboxy group attached through a tether to the 2-N of the ring system, was potent against both isoforms, with ca. . 35 The precise binding mode of 32 to the PARPs will be the subject of later studies.
The most selective inhibitor of PARP-2 identified in our study, 5-benzamidoisoquinolin-1-one 15a, together with the non-isoform-selective lead inhibitor 1 and examples 15l-n of 5-(bulky alkyl)amidoisoquinolin-1-ones which are poorly active against both isoforms, were evaluated for cytotoxicity towards a panel of three diverse human carcinoma cell lines and one human fibroblast cell line in vitro using the MTS colorimetric assay. None of the isoquinolin-1-ones were active against HT29 human colon carcinoma cells or the FEK4 normal human fibroblasts (Table 2 ). Two compounds, 1 and the most selective PARP-2 inhibitor 15a
were very weakly cytotoxic towards the MDA-MB-231 human breast carcinoma cells and two, 15a and 15n, were weakly cytotoxic towards the LNCaP human prostate carcinoma cells. These results are consistent with our previous observation that 1 caused only 40% inhibition of the proliferation of CT26 murine colon carcinoma cells at the very high concentration of 1 mM. 57 None of the cell lines used here have mutant BRCA, so the lack of cytotoxicity is unsurprising.
Post facto structural studies
Post facto molecular modelling studies were undertaken to rationalise the strong selectivity for inhibition of PARP-2 observed for the 5-benzamidoisoquinolin-1-one 15a and for the smaller but significant selectivity observed for the carboxylic acid 29; these represent the most isoform-selective examples from each of the two series originally designed. These post facto studies were aided by the disclosure in 2009 (after the current experimental work had been completed) of a crystal structure of human PARP-1 58 and in 2010 of a crystal structure of human PARP-2 complexed with ABT888 4. 59 Starting structures were taken from published X-ray crystallographic structures of human PARP-1 complexed with a quinoxalinone inhibitor (A861696) 58 and of murine PARP-2 without an inhibitor ligand. 48 The latter was compared with the more recent data for human PARP-2 obtained with 3-aminobenzamide bound; 59 this comparison was used to drive docking and to refine the nicotinamide / inhibitor-binding pocket of PARP-2. Non-selective inhibitor 1 and PARP-2-selective inhibitors 15a and 29 were then docked into the models using the existing bound inhibitor (for PARP-1) and the docked inhibitor (for PARP-2) as templates. Once docked, the inhibitors were subjected molecular mechanics and dynamics calculations to establish optimal docking conformations; during these calculations, the receptor was restrained to its original conformation. Lastly, both the inhibitors and binding pockets (radius 10Å) were subjected to molecular dynamics and finally molecular mechanics calculations to give the final structures ( Figure 3 Differences between the binding pockets of PARP-1 and PARP-2 can be observed from the models. The binding pocket in PARP-1 is smaller than that of PARP-2. Furthermore, the and 29 but inhibition of PARP-1 activity was also strong. The modest selectivity was rationalised by post facto modelling studies.
The 5-amidoisoquinolin-1-ones were investigated as more hydrolytically stable analogues of the benzoate ester 10, for which Pellicciari et al. claimed 60-fold selectivity for inhibition of PARP-2. 33, 56 Of this series, the simple benzamide 15a, the closest analogue of 10, proved to be the most selective (IC 50 (PARP-1) / IC 50 (PARP-2) ) = 9.3. In our comparative assays, 15a had act-ivity equal to that of 10 against PARP-2 but 10 was much more potent than was 15a against PARP-1, leading to an observed selectivity of only 2.75-fold for 10. Similarly, the quinoxaline-5-carboxamide 9b showed a 3-fold selectivity for PARP-1 in our comparative assays, contrasting with a claimed 5-fold selectivity for PARP-2. 39 In the light of these results, it is now evident from our direct comparisons that 5-benzamidoisoquinolin-1-one 15a is the most isoform-selective inhibitor of PARP-2 reported to date. Post facto modelling studies rationalised the structural basis of the observed selectivity.
Acknowledgements
We wish to thank Dr. Timothy J. Woodman (University of Bath) for many of the NMR spectra, Dr. Anneke Lubben (University of Bath) for the mass spectra and Professor Rex M. 
Experimental section
General NMR spectra were recorded on JEOL Delta 270 and Varian Mercury 400 spectrometers.
Mass spectra were obtained using VG7070E and Bruker microTOF™ spectrometers. IR spectra were measured on a Perkin-Elmer RXI FTIR spectrometer. The stationary phase for chromatography was silica gel. All reactions were carried out at ambient temperature, unless otherwise stated. Solvents were evaporated under reduced pressure. Melting points were determined using a Reichert-Jung Thermo Galen instrument and are uncorrected. Concentration of the filtrate and drying gave 1 (1.2 g, 71%) as white crystals: mp 248-252°C
(decomp.) (lit. 15 250-260°C (decomp.)). Crystal data for 33. All data were collected at 150 K on a Nonius kappaCCD diffractometer.
1-Chloro-5-nitroisoquinoline (13
The structure was solved using SHELXS-97 63 and refined using full-matrix least squares in SHELXL-97. 
PARP-2 inhibition assay.
Compounds were assayed for inhibition of the catalytic activity of PARP-2 using a method in which recombinant full-length murine PARP-2 protein (Alexis) (ca. 50 ng) was bound down by a PARP-2-specific antibody in a 96-well white-walled plate.
PARP-2 activity was measured following addition of 3 H-NAD + and DNA. 36 After washing, min, then the other components were added and the reaction allowed to proceed for 45 min.
Data were fitted using a logarithmic concentration scale to a dose-response curve using 15l >200 >200 >200 >200 15m >200 >200 >200 >200 15n >200 >200 42 >200
